Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Revolution Medicines, Inc.
organization4 mentionslast seen Oct 30, 2026
Biopharmaceutical company that developed RASONQUE for metastatic pancreatic adenocarcinoma.
Relationships 7
- Revolution Medicines, Inc.developsRASONQUE99% confidence3 sources
- Revolution Medicines, Inc.developspan-KRAS drug discovery99% confidence2 sources
- Revolution Medicines, Inc.employsYang Liu99% confidence2 sources
- Revolution Medicines, Inc.employsKristof Pota99% confidence2 sources
- Medicilonpartners withRevolution Medicines, Inc.99% confidence2 sources
- Revolution Medicines, Inc.employsMark A. Goldsmith97% confidence1 source
- Revolution Medicines, Inc.developszoldonrasib75% confidence1 source
Relationship
Revolution Medicines, Inc.developsRASONQUE
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- newsPR NewswireOct 30, 2026Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"
Daraxonrasib for metastatic pancreatic cancer
- filingSEC EDGAROct 23, 2026Tango Therapeutics, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
RAS(ON) inhibitors from Revolution Medicines, Inc.
- filingSEC EDGAROct 13, 2026Revolution Medicines, Inc. 8-K: Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Item 8.01: Other Events
Revolution Medicines, Inc. (the "Company"), as borrower, entered into a loan agreement in connection with the U.S. Food and Drug Administration's approval of RASONQUE™